Molecular profiling of tumors
Provided herein are methods and systems of molecular profiling of diseases, such as cancer. In some embodiments, the molecular profiling can be used to identify treatments for a disease, such as treatments that were not initially identified as a treatment for the disease or not expected to be a treatment for a particular disease.
1. A method of identifying one or more candidate treatment for a subject in need of treatment for a cancer, comprising:
(a) performing an immunohistochemistry (IHC) analysis on a sample from the subject on at least: TOP1, TYMS, MGMT, PTEN, ERBB2, and SPARC;
(b) performing a microarray analysis on the sample on at least: TOP1, TYMS, MGMT, PTEN, ERBB2, and SPARC;
(c) performing a fluorescent in-situ hybridization (FISH) analysis on the sample on ERBB2;
(d) performing DNA sequencing analysis on the sample on PIK3CA, KRAS, and BRAF; and
(e) using a computer to access a rules database comprising the biomarker-drug association rules presented in Table 2 and perform all rules in the database for each gene or gene product analyzed in steps a)-d); and
(f) producing a computer generated report based on the rules s performed in step e), wherein the report identifies the one or more candidate treatment.
2. The method of claim 1 , wherein the sample comprises formalin-fixed paraffin-embedded (FFPE) tissue, fresh frozen (FF) tissue, or tissue comprised in a solution that preserves nucleic acid or protein molecules.
3. The method of claim 1 , wherein the sample passes a quality control test.
4. The method of claim 3 , wherein the quality control test comprises an A260/A280 ratio or a Ct value of RT-PCR of RPL13 a mRNA.
5. The method of claim 4 , wherein the sample passes the quality control test if the A260/A280 ratio is >1.5 or the RPL13 a Ct value is >30.
6. The method of claim 1 , wherein the microarray analysis is performed using a low density microarray, an expression microarray, a comparative genomic hybridization (CGH) microarray, a single nucleotide polymorphism (SNP) microarray, a proteomic array or an antibody array.
7. The method of claim 1 , wherein the microarray analysis further comprises microarray analysis of at least CD52.
8. The method of claim 1 , wherein the IHC analysis further consists of IHC analysis of one or more of DCK, EGFR, BRCA1, KRT14 (CK 14), KRT17 (CK 17), KRT 5/6 (CK 5/6), CDH1 (E-Cadherin), NBN (p95), PARP1, and TLE3.
9. The method of claim 1 , wherein the IHC analysis further consists of IHC analysis of PTGS2 (Cox-2) and/or MKI67 (Ki-67).
10. The method of claim 1 , wherein the microarray analysis further consists of microarray analysis of HSP90AA1 (HSPCA).
11. The method of claim 1 , wherein the FISH analysis further consists of FISH analysis of MYC (c-Myc) and/or TOP2A.
12. The method of claim 1 , wherein said microarray analysis comprises identifying a statistical significance level for whether a gene is upregulated or downregulated relative to a reference.
13. The method of claim 12 , wherein the statistical significance is determined at a p-value of less than or equal to 0.05.
14. The method of claim 13 , wherein the p-value is corrected for multiple comparisons.
15. The method of claim 14 , wherein the correction for multiple comparisons comprises Bonneferoni's correction or a modification thereof.
16. The method of claim 1 , wherein the IHC analysis comprises determining whether 30% or more of said sample is +2 or greater in staining intensity.
17. The method of claim 1 , wherein the rules contained within the rules database are based on the efficacy of various treatments particular for a target gene or gene product.
18. The method of claim 1 , wherein a prioritized list of candidate treatments are identified.
19. The method of claim 18 , wherein prioritizing comprises ordering the treatments from higher priority to lower priority according to obtaining usable analysis results for a gene or its gene products using: 1) microarray analysis and either IHC or FISH analysis; 2) IHC analysis but not microarray analysis; and 3) microarray analysis but not IHC analysis.
20. The method of claim 1 , further comprising administration of the one or more candidate treatment to the subject.
21. The method of claim 20 , wherein the one or more candidate treatment comprises 5-fluorouracil, abarelix, Alemtuzumab, aminoglutethimide, Anastrazole, aromatase inhibitors (anastrazole, letrozole), asparaginase, aspirin, ATRA, azacitidine, bevacizumab, bexarotene, Bicalutamide, bortezomib, calcitriol, capecitabine, Carboplatin, celecoxib, Cetuximab, Chemoendocrine therapy, cholecalciferol, Cisplatin, carboplatin, Cyclophosphamide, Cyclophosphamide/Vincristine, cytarabine, dasatinib, decitabine, Doxorubicin, Epirubicin, Erlotinib, Etoposide, exemestane, fluoropyrimidines, Flutamide, fulvestrant, Gefitinib, Gefitinib combined with Trastuzumab, Gemcitabine, gonadorelin, Goserelin, hydroxyurea, Imatinib, Irinotecan, Ixabepilone, Lapatinib, Letrozole, Leuprolide, liposomal doxorubicin, medroxyprogesterone, megestrol, methotrexate, mitomycin, nab-paclitaxel, octreotide, Oxaliplatin, Paclitaxel, Panitumumab, pegaspargase, pemetrexed, pentostatin, sorafenib, sunitinib, Tamoxifen, Tamoxifen-based treatment, Temozolomide, topotecan, toremifene, Trastuzumab, VBMCP/Cyclophosphamide, Vincristine, or any combination thereof.
22. The method of claim 20 , wherein the one or more candidate treatment comprises 5FU, bevacizumab, capecitabine, cetuximab, cetuximab+gemcitabine, cetuximab+irinotecan, cyclophospohamide, diethylstibesterol, doxorubicin, erlotinib, etoposide, exemestane, fluoropyrimidines, gemcitabine, gemcitabine+etoposide, gemcitabine+pemetrexed, irinotecan, irinotecan+sorafenib, lapatinib, lapatinib+tamoxifen, letrozole, letrozole+capecitabine, mitomycin, nab-paclitaxel, nab-paclitaxel+gemcitabine, nab-paclitaxel+trastuzumab, oxaliplatin, oxaliplatin+5FU+trastuzumab, panitumumab, pemetrexed, sorafenib, sunitinib, sunitinib, sunitinib+mitomycin, tamoxifen, temozolomide, temozolomide+bevacizumab, temozolomide+sorafenib, trastuzumab, vincristine, or any combination thereof.
23. The method of claim 1 , wherein the sample comprises cancer cells.
24. The method of claim 1 , wherein the subject has been previously treated with one or more therapeutic agents to treat the cancer.
25. The method of claim 1 , wherein the subject has not previously been treated with one or more candidate therapeutic agents identified in step (f).
26. The method of claim 1 , wherein the cancer comprises a metastatic cancer.
27. The method of claim 1 , wherein the cancer is refractory to a prior treatment.
28. The method of claim 27 , wherein the prior treatment comprises the standard of care for the cancer.
29. The method of claim 1 , wherein the cancer comprises a prostate, lung, melanoma, small cell (esopha/retroperit), cholangiocarcinoma, mesothelioma, head and neck (SCC), pancreas, pancreas neuroendocrine, small cell, gastric, peritoneal pseudomyxoma, anal canal (SCC), vagina (SCC), cervical, renal, eccrine seat adenocarinoma, salivary gland adenocarinoma, uterine soft tissue sarcoma (uterine), GIST (Gastric), or thyroid-anaplastic cancer.
30. The method of claim 1 , wherein the cancer comprises a cancer of the accessory, sinuses, middle and inner ear, adrenal glands, appendix, hematopoietic system, bones and joints, spinal cord, breast, cerebellum, cervix uteri, connective and soft tissue, corpus uteri, esophagus, eye, nose, eyeball, fallopian tube, extrahepatic bile ducts, mouth, intrahepatic bile ducts, kidney, appendix-colon, larynx, lip, liver, lung and bronchus, lymph nodes, cerebral, spinal, nasal cartilage, retina, eye, oropharynx, endocrine glands, female genital, ovary, pancreas, penis and scrotum, pituitary gland, pleura, prostate gland, rectum renal pelvis, ureter, peritonem, salivary gland, skin, small intestine, stomach, testis, thymus, thyroid gland, tongue, unknown, urinary bladder, uterus, vagina, labia, or vulva.
31. The method of claim 1 , wherein the sample comprises cells selected from the group consisting of adipose, adrenal cortex, adrenal gland, adrenal gland - medulla, appendix, bladder, blood, blood vessel, bone, bone cartilage, brain, breast, cartilage, cervix, colon, colon sigmoid, dendritic cells, skeletal muscle, enodmetrium, esophagus, fallopian tube, fibroblast, gallbladder, kidney, larynx, liver, lung, lymph node, melanocytes, mesothelial lining, myoepithelial cells, osteoblasts, ovary, pancreas, parotid, prostate, salivary gland, sinus tissue, skeletal muscle, skin, small intestine, smooth muscle, stomach, synovium, joint lining tissue, tendon, testis, thymus, thyroid, uterus, and uterus corpus.
32. The method of claim 1 , wherein the cancer comprises a breast, colorectal, ovarian, lung, non-small cell lung cancer, cholangiocarcinoma, mesothelioma, sweat gland, or GIST cancer.
33. The method of claim 20 , wherein progression free survival (PFS) or disease free survival (DFS) for the subject is extended by administration of the one or more candidate therapeutic agents to the subject.
34. The method of claim 33 , wherein PFS or DFS is extended by at least 30% compared to prior treatment.
35. The method of claim 20 , wherein the subject's lifespan is extended by administration of the one or more candidate therapeutic agents to the subject.
36. The method of claim 35 , wherein the patient's lifespan is extended by at least 4 weeks.
37. The method of claim 1 , wherein the cancer comprises a colorectal cancer.
38. The method of claim 1 , wherein the IHC analysis further consists of IHC analysis of at least one additional biomarker selected from the group consisting of: PGP, ER, PR, KIT, AR, CD52, PDGFRB, TOP2A, ERCC1, RRM1, ABCG2 (BCRP) and MRP1.
39. The method of claim 38 , wherein the IHC analysis is performed on at least 50% of the additional biomarkers.
40. The method of claim 38 , wherein the IHC analysis profiling is performed on all of the additional biomarkers.
41. The method of claim 1 , wherein the microarray analysis further consists of microarray analysis of at least one additional biomarker selected from the group consisting of: ABCC1, ABCG2, ADA, AR, ASNS, BCL2, BIRC5, BRCA1, BRCA2, CD33, CD52, CDA, CES2, DCK, DHFR, DNMT1, DNMT3A, DNMT3B, TYMP (ECGF1), EGFR, EPHA2, ERCC1, ERCC3, ESR1, FLT1, FOLR2, FYN, GART, GNRH1, GSTP1, HCK, HDAC1, HIF1A, HSP9OAA1, IL2RA, KDR, KIT, LCK, LYN, MLH1, MS4A1, MSH2, NFKB1, NFKB2, OGFR, PDGFC, PDGFRA, PDGFRB, PGR, POLA1, PTGS2, RAF1, RARA, RRM1, RRM2, RRM2B, RXRB, RXRG, SRC, SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, TK1, TNF, TOP2A, TOP2B, TXNRD1, VDR, VEGFA, VHL, YES1, ZAP70, and a combination thereof.
42. The method of claim 41 , wherein the microarray analysis is performed on at least 50% of the additional biomarkers.
43. The method of claim 41 , wherein the microarray analysis is performed on all of the additional biomarkers.
44. The method of claim 1 , wherein the FISH analysis further consists of FISH analysis of EGFR.
45. The method of claim 1 , wherein the sequencing analysis further consists of DNA sequence analysis of KIT and/or EGFR.
46. The method of claim 1 , wherein the report lists the one or more identified candidate treatment and the biomarker-drug association rules used to identify the one or more identified candidate treatment.
47. The method of claim 1 , wherein the report comprises a summary listing of the IHC analysis, microarray analysis, FISH analysis and sequencing analysis.
48. The method of claim 1 , wherein the report is displayed using a computer display or a printed report.